UCB says partnerships boost UK economy
UCB says that pharma-university collaborations can help the UK economy flourish.
Read MoreAuthor: Ben Adams
Psoriasis is more than skin deep, says NICE
NICE is issuing new guidelines aimed at getting family doctors to think about how psoriasis might be affecting the daily lives of their patients.
Read MorePfizer to acquire NextWave for $700m
Pfizer has set its acquisition crosshairs on Californian ADHD specialist NextWave, and looks set to spend $700m to buy the company.
Read MoreCost of prescribing in UK dips
The UK government has released new figures showing that the cost of prescribing drugs has fallen.
Read MoreEylea and Lucentis matched in new study
Bayer and Regeneron’s eye drug Eylea has matched its rival Lucentis in a new head-to-head trial.
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
